These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33034810)

  • 1. A possible effect of montelukast on neurological aging examined by the use of register data.
    Grinde B; Schirmer H; Eggen AE; Aigner L; Engdahl B
    Int J Clin Pharm; 2021 Jun; 43(3):541-548. PubMed ID: 33034810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
    Mohamed MZ; Zenhom NM
    Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified.
    Grinde B; Engdahl B
    Immun Ageing; 2017; 14():20. PubMed ID: 28874912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients.
    Di Salvo E; Patella V; Casciaro M; Gangemi S
    Pulm Pharmacol Ther; 2020 Feb; 60():101875. PubMed ID: 31837440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
    Wallin J; Svenningsson P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
    Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
    Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Airway mechanics after withdrawal of a leukotriene receptor antagonist in children with mild persistent asthma: Double-blind, randomized, cross-over study.
    Kim JH; Lee S; Shin YH; Ha EK; Lee SW; Kim MA; Yoon JW; Baek HS; Choi SH; Han MY
    Pediatr Pulmonol; 2020 Dec; 55(12):3279-3286. PubMed ID: 32965787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.
    Michael J; Zirknitzer J; Unger MS; Poupardin R; Rieß T; Paiement N; Zerbe H; Hutter-Paier B; Reitsamer H; Aigner L
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
    Yu GL; Wei EQ; Zhang SH; Xu HM; Chu LS; Zhang WP; Zhang Q; Chen Z; Mei RH; Zhao MH
    Pharmacology; 2005 Jan; 73(1):31-40. PubMed ID: 15452361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review.
    El-Alali EA; Abukhiran IM; Alhmoud TZ
    BMC Gastroenterol; 2021 Jul; 21(1):279. PubMed ID: 34238222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis.
    Krishnamoorthy M; Mohd Noor N; Mat Lazim N; Abdullah B
    Drugs; 2020 Nov; 80(17):1831-1851. PubMed ID: 32915441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
    Al-Amran FG; Hadi NR; Hashim AM
    Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury.
    Biber N; Toklu HZ; Solakoglu S; Gultomruk M; Hakan T; Berkman Z; Dulger FG
    Brain Inj; 2009 Jun; 23(6):577-84. PubMed ID: 19484631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 trial of montelukast for prevention of pain in sickle cell disease.
    Field JJ; Kassim A; Brandow A; Embury SH; Matsui N; Wilkerson K; Bryant V; Zhang L; Simpson P; DeBaun MR
    Blood Adv; 2020 Mar; 4(6):1159-1165. PubMed ID: 32208487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.
    Bateman ED; Goehring UM; Richard F; Watz H
    J Allergy Clin Immunol; 2016 Jul; 138(1):142-149.e8. PubMed ID: 26915674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with montelukast and antidepressive medication-a symmetry analysis.
    Winkel JS; Damkier P; Hallas J; Henriksen DP
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1409-1415. PubMed ID: 30136330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory medications for the treatment of pediatric obstructive sleep apnea.
    Kuhle S; Urschitz MS
    Paediatr Respir Rev; 2020 Apr; 34():35-36. PubMed ID: 32245548
    [No Abstract]   [Full Text] [Related]  

  • 18. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma.
    Reicin A; White R; Weinstein SF; Finn AF; Nguyen H; Peszek I; Geissler L; Seidenberg BC
    Arch Intern Med; 2000 Sep; 160(16):2481-8. PubMed ID: 10979060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury.
    Erşahin M; Çevik Ö; Akakın D; Şener A; Özbay L; Yegen BC; Şener G
    Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):131-9. PubMed ID: 22986158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
    Said MM; Bosland MC
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.